Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and Artificial Neural Networks

Hepato-Gastroenterology

Volumn 59, Issue 120, 2012, Pages 2461-2465

  Yuan, Ying ^a   Tan, Chun Wen ^a   Shen, Hong ^a   Yu, Jie Kai ^a   Fang, Xue Feng ^a   Jiang, Wen Zhi ^a   Zheng, Shu ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Artificial neural networks; Chemotherapy; Colorectal cancer; Protein pattern; Surface enhanced laser desorption ionization time of flight mass spectrometry

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER CHEMOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PROTEINS; CAMPTOTHECIN; CHINA; COLORECTAL NEOPLASMS; DECISION SUPPORT TECHNIQUES; FLUOROURACIL; HUMANS; LEUCOVORIN; NEURAL NETWORKS (COMPUTER); ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84872069927     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge12127     Document Type: Article

References (14)

1. Jemal A, Siegel R, Xu J, et al.: Cancer Statistics, 2010. CA Cancer J Clin 2010; 60:277-300.
2. Pelley RJ: Oxaliplatin: a new agent for colorectal cancer. Curr Oncol Rep 2001; 3:147-155.
3. Vanhoefer U, Harstrick A, Achterrath W, et al.: Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19:1501-1518.
4. Douillard JY, Cunningham D, Roth AD, et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomized trial. Lancet 2000; 355:1041-1047.
5. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
6. Li J, Zhang Z, Rosenzweig J, et al.: Proteomics and bioinformatics approached for identification of serum biomarkers to detect breast cancer. Clin Chem 2002; 48:1296-304.
7. Mok SC, Chao J, Skates S, et al.: Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 2001; 93:1458-1464.
8. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15:24-30.
9. Petricoin EF, Ardekani AM, Hitt BA, et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359:572-577.
10. Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, et al.: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005; 5:3790-3797.
11. Shanbhogue AK, Karnad AB, Prasad SR: Tumor response evaluation in oncology: current update. J Comput Assist Tomogr 2010; 34(4):479-484.
12. Mariadason JM, Arango D, Augenlicht LH: Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resist Updat 2004; 7:209-218.
13. Smith FM, Gallagher WM, Fox E, et al.: Combination of SELDI-TOF-MS and data mining provides early-stage response prediction for rectal tumors undergoing multimodal neoadjuvant therapy. Ann Surg 2007; 245(2):259-266.
14. Hayashida Y, Honda K, Osaka Y, et al.: Possible prediction of chemoradiosensitivity of esophageal cancer by serum protein profiling. Clin Cancer Res 2005; 11(22):8042-8047.